Genetic, experimental and clinical studies have consistently confirmed that inhibition of proprotein
convertase subtilisin/kexin type 9 (PCSK9) can result in significant LDL-C lowering and two fully human
PCSK9 mononclonal antibodies have received regulatory approval for use in high-risk patients. Co-
administration of PCSK9 with statins has resulted in extremely low LDL-C levels with excellent short-term
safety profiles. While results from Phase III clinical trials provided exciting evidence about the role of
PCSK9 inhibitors in reducing cardiovascular event rates, their impact on mortality remains less clear.
PCSK9 inhibitor therapy can be considered for high risk patients who are likely to experience the largest
cardiovascular risk reduction benefit.
Keywords: PCSK9, Proprotein Convertase Subtilisin/Kexin type 9, Alirocumab, Evolocumab, LDL-cholesterol,
Rights & PermissionsPrintExport